Latest Management of cancer Stories
Following several years of study, investigators have found more evidence that viral therapy to treat solid tumors can be enhanced by blocking the body’s natural immune response. Oncolytic viruses have shown promise as anticancer agents, with variations of the herpes simplex virus (HSV) among the most commonly used. However, many studies have shown that the effectiveness of viral therapy to eradicate tumors has not been as successful with patients as it has been in the lab. These results...
Findings suggest value of Oncotype DX in tailoring radiation therapy treatment for select node-positive patients treated with hormonal therapy and chemotherapy REDWOOD CITY, Calif., March 13, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced positive results of a large study that demonstrates the Oncotype DX® Recurrence Score® result to be a robust predictor of loco-regional recurrence (LRR) in node-positive (N+), estrogen receptor (ER) positive patients...
MarginProbe System significantly reduced pathologically positive margins following initial lumpectomy compared to traditional intra-operative methods WASHINGTON, March 7, 2013 /PRNewswire/ -- Dune Medical Devices, Inc., announced today that results from the pivotal clinical trial for the MarginProbe System, Dune's breakthrough intra-operative tissue assessment tool for early-stage breast cancer surgery, were presented at the 66(th) Annual Society of Surgical Oncology (SSO) Cancer...
Support is Necessary to Balance Health and Work Demands NEW YORK, March 5, 2013 /PRNewswire/ -- Nearly 80 percent of cancer patients and survivors say continuing work after diagnosis aids recovery, according to a new survey from Cancer and Careers and Harris Interactive. Still, just as many respondents struggle to find support navigating the work/life balance of employment with cancer - which is where Cancer and Careers offers assistance. As the only organization in the U.S....
HAYWARD, Calif., March 4th, 2013 /PRNewswire/ -- Advanced Cell Diagnostics, Inc. (ACD) announced today that they have entered into an agreement with The Johns Hopkins University on behalf of its Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins to use ACD's proprietary RNAscope® technology platform to validate novel biomarkers and drug targets for cancer immunotherapy. Cancer immunotherapy, which aims to mobilize a patient's immune system to fight cancer, has been gaining...
Bel Marra Health, who offers high-quality, specially formulated vitamins and nutritional supplements, is reporting on a new research that shows the success of software originally used for star gazing and how it is now being used to analyze breast cancer tissue. Toronto, ON (PRWEB) March 03, 2013 Bel Marra Health, who offers high-quality, specially formulated vitamins and nutritional supplements, is reporting on a new research that shows the success of software originally used for star...
Here are five ways cancer caregivers can avoid burn out based on tips from those who have fought—or are still fighting—the cancer battle with their loved one. Seattle, Wash. (PRWEB) March 01, 2013 5 Ways Cancer Caregivers Can Avoid Burn out When a loved one is fighting cancer, it’s easy to overlook the load caregivers often face. Not only do they shoulder the responsibility of caring for the patient (sometimes around the clock), but they also juggle a combination of kids, work and,...
New flagship linear accelerator designed to deliver higher-quality radiation therapy for more patients, more cancer types ATLANTA and STOCKHOLM, March 1, 2013 /PRNewswire/ -- During a live global event, Elekta announced the launch of Versa HD(TM), an advanced linear accelerator system designed to improve patient care and treat a broader spectrum of cancers. Featuring high precision beam shaping and tumor targeting, Versa HD also unveils new capabilities designed to maximize health...
SAN DIEGO, Feb. 28, 2013 /PRNewswire/ --Aethlon Medical, Inc. (OTCQB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. I recently attended a healthcare related event that featured a panel discussion comprised of life science bankers and venture capitalists. While members of this panel often had differing viewpoints, they did mutually agree they were interested in emerging therapeutic candidates that provided more than one "shot on goal," meaning...
First Study Ever to Analyze 25 years of Data after Radiation Therapy for Prostate Cancer Patients ATLANTA, Feb. 26, 2013 /PRNewswire/ -- The March 2013 issue of The Journal of Urology, the official journal of The American Urological Association, includes a study conducted by four physicians from Radiotherapy Clinics of Georgia (RCOG), a Vantage Oncology affiliate. This study, 25 Year Disease Free Survival Rate after Irradiation of Prostate Cancer Calculated with the Prostate...
